Results 41 to 50 of about 37,448 (280)

Oral Candidiasis: A Disease of Opportunity [PDF]

open access: yesJournal of Fungi, 2020
Oral candidiasis, commonly referred to as “thrush,” is an opportunistic fungal infection that commonly affects the oral mucosa. The main causative agent, Candida albicans, is a highly versatile commensal organism that is well adapted to its human host; however, changes in the host microenvironment can promote the transition from one of commensalism to ...
Taissa Vila   +3 more
openaire   +3 more sources

FUNGAL DISEASE OF THE ORAL CAVITY

open access: yesМедицинский совет, 2017
The problem of oral candidiasis is topical for the adult population and children due to frequent recurrence, the presence of a large number of predisposing factors, lack of compliance with hygienic measures for the care of the oral cavity.
L. N. DROBOTKO   +3 more
doaj   +1 more source

Neonatal thrush of newborns: Oral candidiasis? [PDF]

open access: yes, 2019
Objectives: Neonatal thrush, also called oral candidiasis, is commonly a clinical diagnosis based on white patches on oral mucosal surfaces. Candida albicans is often associated with it.
Tuomi, J. (Jenni)   +11 more
core   +1 more source

Effect of oral hygiene in infants before dental eruption on Candida spp. colonization and the occurrence of oral candidiasis: A randomized clinical trial [PDF]

open access: yes, 2023
BACKGROUND: To assess the influence of oral hygiene in infants before the primary tooth eruption on colonization by Candida spp. and the occurrence of oral candidiasis.
Ramos-Jorge, Joana   +10 more
core   +2 more sources

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

Oral Candidiasis and Human-Immunodeficiency-Virus Infection [PDF]

open access: yes, 1989
The association of oral candidiasis with the human immunodeficiency virus (HIV) infection has been known since the advent of the acquired immunodeficiency syndrome (AIDS) pandemic.
Palle Holmstrup   +3 more
core   +1 more source

Does YouTube™ provide reliable information on oral candidiasis? [PDF]

open access: yes, 2022
Objective: To evaluate the quality, source, usefulness and/or reliability, visibility, and popularity of Youlube (TM) videos on oral candidiasis. Materials and Methods: A YouTube (TM) search for "oral candidiasis" was performed, setting the English ...
Paksoy, Tuğçe   +2 more
core   +1 more source

Use of Clotrimazole in Finfish Aquaculture: Mechanistic Insights, Limitations, and Future Directions for Antifungal Therapy

open access: yesAnimal Research and One Health, EarlyView.
This review critically evaluates clotrimazole as a potential antifungal for finfish aquaculture, highlighting strong mechanistic and in vitro efficacy against aquatic mycoses alongside major gaps in in vivo evidence, toxicokinetics, residue safety, and environmental risk, outlining priorities for responsible therapeutic development and regulatory ...
Arya Sen   +2 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Clinical features and risk factors for Sjogren’s syndrome patients suffering from oral candidiasis in Shanxi, China

open access: yesBMC Oral Health
Objectives To investigate the clinical features and risk factors of Sjogren’s Syndrome (SS) patients suffering from oral candidiasis and to provide a foundation for the prevention and treatment of oral candidiasis in SS patients.
Yexing Xing   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy